stockrow
Monday 9 November 2026
Export LTGO’s income statement to Excel — free account
Latigo Biotherapeutics Inc
LTGO
13.43
0.83
+6.59%
Follow LTGO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 21 | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | (129.23) | — | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | 0.00 | 13.37 | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | 1 | — | — | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | 8 | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | (55) | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | 13 | — | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 59 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Latigo Biotherapeutics Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience, Inc. | $987.3M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| CTY City Therapeutics, Inc | $943.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $914.2M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $908.6M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $903.2M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $869.9M | 34.1× | 47.1× | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $858.9M | — (loss-making) | — (loss-making) | +81.59% (above 0%: growing) | n/m | +61.43% (above 0%: growing) | 83.20% | (50.30%) | Compare |
| LTGO Latigo Biotherapeutics Inc | $835.4M | — | — | — | n/m | — | — | 0.00% | |
| RIGL Rigel Pharmaceuticals, Inc. | $746.6M | 2.4× | 12.6× | +16.45% (above 0%: growing) | −54.84% (below 0%: shrinking) | +43.90% (above 0%: growing) | 86.67% | 21.15% | Compare |
| Median of peers | $905.9M | — | — | +20.86% | — | −3.42% | 84.94% | 0.00% |